Introduction {#sec1-1}
============

Spinal cord injury (SCI) is associated with high morbidity and severe complications. Effective treatments are lacking, resulting in an enormous financial and social burden on patients, their families and society (Phillips et al., 2015). SCI leads to severe neurological impairments, including motor, sensory and autonomic dysfunction. The secondary injury results in lesions extending out from the primary focus of damage, greatly worsening the damage caused by the initial trauma (Aslan et al., 2009; Elamin et al., 2013). The secondary injury includes oxidative stress and inflammatory response. Oxidative stress, which occurs when the production of reactive oxygen species exceeds the capacity of the antioxidant system, plays a major role in secondary SCI (Paterniti et al., 2009; Khayrullina et al., 2015). Along with an increase in the production of inflammatory factors (Didangelos et al., 2014), this results in a strong inflammatory response (Genovese et al., 2009; Ni et al., 2014). Inhibiting inflammation influences recovery from SCI (Ji, 2014; Machova et al., 2015; Chen and Jin, 2016).

Mitogen-activated protein kinase (MAPK) is involved in signal transduction for apoptosis (Pereira et al., 2013), and its levels predict whether the cell survives or dies, as they reflect damage to the cell (Yamaoka et al., 2012; Nafees et al., 2015). The expression of MAPK is upregulated during the apoptotic process in neurons and glial cells after SCI (Lee et al., 2010; Ha et al., 2011). Besides, the expression of MAPK could mediate the inflammatory response (Breton-Romero and Lamas, 2013).

Currently, there is no treatment for SCI that results in complete neurological or functional recovery (Varma et al., 2013). Rutin is a flavonoid of the flavonol type found widely in plants, including foods; it has a wide range of biological activities, and has a protective effect on experimental acute pancreatitis, and also inhibits cell proliferation and induces apoptosis (Zhang et al., 2015).

Rutin protects against liver and lung injury through antioxidative and anti-inflammatory actions and by modulating the MAPK pathway (Pan et al., 2014; Yeh et al., 2014). However, there is no report regarding the neuroprotective effects of rutin on SCI. In our study, we first investigated the neuroprotective effects of rutin in a rat model of SCI and examined the underlying mechanisms.

Materials and Methods {#sec1-2}
=====================

Animals {#sec2-1}
-------

Totally 40 male Sprague-Dawley rats, at 8 weeks of age, weighing 200--230 g, were provided by the Animal Center of Shandong University of China (SCXK (Lu) 2013 0009). The rats were housed in individual cages under controlled conditions (22--24°C, relative humidity of 40--60%, with a 12-hour light-dark cycle and free access to food and water).

The experimental procedure followed the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1985). The study protocol was approved by the Animal Ethics Committee of Jinan Central Hospital Affiliated to Shandong University of China (2014-30).

Chemicals and reagents {#sec2-2}
----------------------

Rutin (powder, purity \> 98%) was purchased from Nanjing University of Traditional Chinese Medicine, Institute of Chinese Materia Medica (Nanjing, China), and prepared into solution 6 g/L with double distilled water, and its chemical structure is shown in [**Figure 1**](#F1){ref-type="fig"}.

![Chemical structure of rutin.](NRR-13-128-g002){#F1}

Generation of the rat SCI model {#sec2-3}
-------------------------------

The SCI model was generated as described previously (Ravikumar et al., 2005). The rats were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) and a mixture of ketamine (44 mg/kg; Sangon Biotech, Shanghai, China), atropine (0.02633 mg/kg; Sintong Chemical Industrial Co., Taoyuan, Taiwan, China) and xylazine (5 mg/kg; Sangon Biotech, Shanghai, China). The T~8~ and T~9~ vertebral peduncles were removed by laminectomy. After that, the moderate contusion injury was performed by a modified Allen\'s weight drop apparatus (10 g weight at 50 mm, 10 g × 50 mm) on the exposed spinal cord. For the control rats, the same laminectomy was performed, but without SCI. The success of the compression can be confirmed by the spasm of the tail, the retraction-like flutter of legs and delayed paralysis.

Drug treatment {#sec2-4}
--------------

The rats were randomly divided into the following four groups: (1) control (*n* = 10), consisting of normal rats performed with laminectomy without spinal cord compression and treated with PBS; (2) SCI model (SCI, *n* = 10), consisting of rats with SCI treated with PBS; (3) methylprednisolone (MP, *n* = 10), consisting of rats with SCI treated with 100 mg/kg methylprednisolone once a day for 3 day. (intraperitoneally; Jinan Central Hospital Affiliated to Shandong University, China); (4) rutin (rutin, *n* = 10), consisting of rats with SCI treated with rutin 30 mg/kg, intraperitoneally) once a day for 3 days. All the treatments were performed at 6 hours after the injury happened.

Assessment of locomotor function {#sec2-5}
--------------------------------

Locomotor function was evaluated using the Basso, Beattie and Bresnahan (BBB) score. A lower BBB score indicates more severe motor impairment. The rating scale ranges from 0 (no observable hindlimb movement) to 21 (normal locomotion) (Basso et al., 1996). BBB scores were assessed by four experienced experimenters who were blinded to the treatment conditions. BBB score was observed for 24, 48, 72 hours, 7 days after surgery.

Determination of spinal cord water content {#sec2-6}
------------------------------------------

After treatment with rutin for 3 days, the water content of the spinal cord was evaluated. All rats were killed by excess chloral hydrate, and the spinal cord samples were dried for 48 hours at 80°C for the determination of the dry weights. The water content of the spinal cord was calculated as follows: (wet weight − dry weight)/wet weight × 100%.

Measurement of oxidative stress {#sec2-7}
-------------------------------

After treatment with rutin for 3 days, the peripheral blood was carefully collected from heart in each group. The blood samples were centrifuged at 12,000 × *g* for 10 minutes at 4°C. The supernatant was collected, and the concentrations of malon dialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT), as well as glutathione peroxidase (GSH-Px) activity were analyzed using commercial kits, following the manufacturer\'s protocols (Beyotime, Nanjing, China).

Assessment of inflammation {#sec2-8}
--------------------------

After treatment with rutin for 3 days, approximately 5 mL peripheral blood was collected from heart directly of each group. The blood samples collected from heart were centrifuged at 12,000 × *g* for 10 minutes at 4°C. The supernatant was collected, and the serum levels of nuclear factor-κB (NF-κB) p65 unit, tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β and IL-6 were measured using commercial kits, following the manufacturer\'s protocols (Beyotime, Nanjing, China).

Western blot assay of p38MAPK protein expression {#sec2-9}
------------------------------------------------

After treatment with rutin for 3 days, rats were scarified and approximately 15 cm long spinal cord containing T~8~ and T~9~ were taken out for further testing. 10-mg spinal cord tissue samples were incubated with 100 μL tissue lysis buffer (Beyotime) for 30 minutes on ice. Homogenates were centrifuged at 12,000 × *g* for 10 minutes at 4°C. The supernatants were collected, and the protein concentration was determined using a bicinchoninic acid kit (KeyGen Biotech). Equal amounts of protein were resolved on 12% sodium dodecyl sulfate-polyacrylamide gel electropheresis gels and then transferred to polyvinylidene fluoride membranes (0.22 μm). Membranes were blocked with PBS containing 5% non-fat milk to block nonspecific binding. Then, the membranes were incubated with anti-p38 MAPK mouse monoclonal antibody (1:2,000; sc-398305, Santa Cruz Biotechnology, Dallas, TX, USA) and anti-β-actin rabbit polyclonal antibody (1:500; D110007, Sangon Biotech, Shanghai, China) overnight at 4°C, followed by incubation with horseradish peroxidase-conjugated anti-mouse IgG (1:1,000; sc-2005 and sc-2004, Santa Cruz Biotechnology) for 2 hours at room temperature (24--26°C). Signals were quantified using the Gel Doc XR+ Gel Documentation System (Bio-Rad, Hercules, CA, USA). Grayscale value (/internal reference) was detected by the image J software (NIH, Bethesda, Maryland, USA).

Measurement of caspase-9 and caspase-3 activities {#sec2-10}
-------------------------------------------------

After treatment with rutin for 3 days, spinal cord protein samples were obtained as described above, and equal amounts of protein were mixed with reaction buffer (Ac-LEHD-pNA for caspase-9, Ac-DEVD-pNA for caspase-3) and incubated at 37°C for 2 hours in the dark. Caspase-9 and caspase-3 activities were measured at an absorbance of 405 nm on a spectrophotometer (Thermo Fisher Scientific, Waltham, NJ, USA). The results of each treatment groups were compared with the control group to obtain relative quantification (absorbance value) of the target proteins\' expression.

Statistical analysis {#sec2-11}
--------------------

Data are presented as the mean ± SD. Statistics was performed using SPSS 20.0 software (IBM Corporation, Armonk, NY, USA). Statistical analysis was conducted using one-way analysis of variance followed by Dunnett\'s *post hoc* test. A *P*-value of less than 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Evaluation of locomotor recovery {#sec2-12}
--------------------------------

We assessed whether rutin affected locomotor recovery in our rat SCI model using the BBB scoring system. As shown in [**Figure 2**](#F2){ref-type="fig"}, BBB scores were reduced at 24, 48 and 72 hours post-surgery in the SCI group, compared with the control group. Treatment with rutin (30 mg/kg day per for 3 days after SCI) and MP resulted in an increase in the BBB score in comparison with the SCI group, and both showed significant difference compared with SCI group (*P* \< 0.05; [**Figure 2**](#F2){ref-type="fig"}). There was no significant difference between the rutin group (30 mg/kg) and MP group (*P* \> 0.05; [**Figure 2**](#F2){ref-type="fig"}).

![BBB scores for evaluating locomotor recovery 24, 48, 72 hours and 7 days after operations.\
\**P* \< 0.01, vs. Con group; \#*P* \< 0.01, vs. SCI group. Data are presented as the mean ± SD (*n* = 10, one-way analysis of variance followed by Dunnett\'s *post hoc* test). Con group was performed with laminectomy without compression, and treated with PBS; SCI group was performed with laminectomy with compression and treated with PBS. MP group was performed with laminectomy with compression and treated with MP (100 mg/kg/perday for 3 days). Rutin group was performed with laminectomy with compression and treated with Rutin (30 mg/kg/per day for 3 days). Con: Control; SCI: spinal cord injury; MP: methylprednisolone; BBB: Basso, Beattie and Bresnahan.](NRR-13-128-g003){#F2}

Rutin reduced spinal cord water content in rats with SCI {#sec2-13}
--------------------------------------------------------

We examined the water content of the spinal cord after 3-day treatment. As shown in [**Figure 3**](#F3){ref-type="fig"}, spinal cord water content was increased in the SCI group compared with the control group. The water content of the spinal cord decreased in the rutin group (30 mg/kg/day for 3 days) compared with the SCI group (*P* \< 0.05; [**Figure 3**](#F3){ref-type="fig"}). Interestingly, the spinal cord water content in the rutin group was very similar to that in the MP group (*P* \> 0.05; [**Figure 3**](#F3){ref-type="fig"}).

![Rutin treatment for 3 days diminishes the SCI-induced increase in water content in the spinal cord.\
\**P* \< 0.01, vs. con group; \#*P* \< 0.01, vs. SCI group. Data are presented as the mean ± SD (*n* = 4, one-way analysis of variance followed by Dunnett\'s *post hoc* test). Con group was performed with laminectomy without SCI and treated with PBS; SCI group was treated with PBS after SCI; MP group was treated with MP (100 mg/kg per day for 3 days) after SCI; Rutin group was treated with Rutin (30 mg/kg/per day for 3 days) after SCI. Con: Control; SCI: spinal cord injury; MP: methylprednisolone.](NRR-13-128-g004){#F3}

Antioxidative effects of rutin in SCI {#sec2-14}
-------------------------------------

After 3 days of treatment, MDA concentration was increased in the SCI group compared with the control group ([**Figure 4A**](#F4){ref-type="fig"}). MDA concentrations were reduced by treatment with rutin, compared to the SCI group ([**Figure 4A**](#F4){ref-type="fig"}). The concentrations of SOD and catalase, and GSH-Px activity were lower in the SCI group, compared to the control group (**Figure [4B](#F4){ref-type="fig"}--[D](#F4){ref-type="fig"}**). Rutin treatment in rats with SCI increased their levels compared with rats in the SCI group (**Figure [4B](#F4){ref-type="fig"}--[D](#F4){ref-type="fig"}**; *P* \< 0.05). We found no significant difference between the rutin and MP groups (*P* \> 0.05; **Figure [4A](#F4){ref-type="fig"}--[D](#F4){ref-type="fig"}**).

![Antioxidative effects on SCI after 3 days of treatment with rutin.\
Effects of rutin on the peripheral blood levels of MDA (A), SOD (B), CAT (C) and GSH-Px (D) in the rat SCI model. \**P* \< 0.01, *vs*. Con group; \#*P* \< 0.01, vs. SCI group. Data are presented as the mean ± SD (*n* = 4, one-way analysis of variance followed by Dunnett\'s *post hoc* test). Con group was performed with laminectomy without SCI and treated with PBS; SCI group was treated with PBS after SCI; MP group was treated with MP (100 mg/kg per day for 3 days) after SCI; Rutin group was treated with rutin (30 mg/kg per day for 3 days) after SCI. Con: Control; SCI: spinal cord injury; MP: methylprednisolone; MDA: malondialdehyde; SOD: superoxide dismutase; CAT: catalase; GSH-Px: glutathione peroxidase; PBS: phosphate buffered saline.](NRR-13-128-g005){#F4}

Anti-inflammatory effects of rutin on SCI {#sec2-15}
-----------------------------------------

As shown in **Figure [5A](#F5){ref-type="fig"}--[D](#F5){ref-type="fig"}**, SCI induced an inflammatory reaction and increased the levels of NF-κB p65, TNF-α, IL-1β and IL-6 in comparison to the control group. However, these inflammatory cytokines were reduced in the rutin group (30 mg/kg/day for 3 days) compared to the SCI group (*P* \< 0.05; **Figure [5A](#F5){ref-type="fig"}--[D](#F5){ref-type="fig"}**). No significant differences in NF-κB p65, TNF-α, IL-1β or IL-6 levels were observed between rutin and MP groups (*P* \> 0.05; **Figure [5A](#F5){ref-type="fig"}--[D](#F5){ref-type="fig"}**).

![Anti-inflammatory effects of 3-day treatment with rutin on SCI.\
Effects of rutin on the serum levels of NF-κB p65 (A), TNF-α (B), IL-1β (C) and IL-6 (D) in the rat models of SCI 72 hours after operation. \**P* \< 0.01, *vs*. Con group; \#*P* \< 0.01, vs. SCI group. Data are presented as the mean ± SD (*n* = 4, one-way analysis of variance followed by Dunnett\'s *post hoc* test). Con group was performed with laminectomy without SCI and treated with PBS. SCI group was treated with PBS after SCI. MP group was treated with MP (100 mg/kg per day for 3 days) after SCI. Rutin group was treated with Rutin (30 mg/kg per day for 3 days) after SCI. Con: Control; SCI: spinal cord injury; MP: methylprednisolone; NF-κB: nuclear factor kappa B; TNF-α: tumor necrosis factor alpha; IL: interleukin.](NRR-13-128-g006){#F5}

Rutin decreased p38MAPK protein expression in the rat models of SCI {#sec2-16}
-------------------------------------------------------------------

There is growing evidence that the protective effects of rutin in SCI involve changes in p38 MAPK expression. p38 MAPK protein expression was substantially increased in the SCI group compared with the control group (**Figure [6A](#F6){ref-type="fig"}, [B](#F6){ref-type="fig"}**). Treatment with rutin (30 mg/kg/day for 3 days) reduced p38 MAPK expression compared with the SCI group (**Figure [6A](#F6){ref-type="fig"}, [B](#F6){ref-type="fig"}**). There was no significant difference in p38 MAPK protein expression between rutin and MP groups (*P* \> 0.05; **Figure [6A](#F6){ref-type="fig"}, [B](#F6){ref-type="fig"}**).

![Rutin decreases p38 MAPK protein expression after 3-day treatment with rutin on SCI.\
Representative western blot bands (A) and densitometric analysis of p38 MAPK protein (B) in the spinal cord. \*\**P* \< 0.01, *vs*. Con group; \#*P* \< 0.05, *vs*. SCI group. Data are presented as the mean ± SD (*n* = 4, one-way analysis of variance followed by Dunnett\'s *post hoc* test). Con group was performed with laminectomy without compression and treated with PBS. SCI group was performed with laminectomy with compression and treated with PBS. MP group was performed with laminectomy with compression and treated with MP (100 mg/kg per day for 3 days). Rutin group was performed with laminectomy with compression and treated with Rutin (30 mg/kg per day for 3 days). Con: Control; SCI: spinal cord injury; MP: methylprednisolone.](NRR-13-128-g007){#F6}

Rutin decreased caspase-9 and caspase-3 activities in rats with SCI {#sec2-17}
-------------------------------------------------------------------

Caspase-9 and caspase-3 activities were increased in the SCI group, compared with the control group (*P* \< 0.05). Rutin reduced the activities of these caspases in the animals with SCI (*P* \< 0.05) (**Figure [7A](#F7){ref-type="fig"}, [B](#F7){ref-type="fig"}**).

![Rutin treatment for 3 days decreases caspase-9 and caspase-3 activities in the SCI rats.\
The effects of rutin on caspase-9 (A) and caspase-3 (B) activities (absorbance value ratio) in rats with SCI in T~8~ and T~9~ spinal cord 72 hours after operation. \**P* \< 0.05, vs. Con group; \#*P* \< 0.05, vs. SCI group. Data are presented as the mean ± SD (*n* = 4, one-way analy-sis of variance followed by Dunnett\'s *post hoc* test). Con group was performed with laminectomy without com-pression and treated with PBS. SCI group was performed with laminectomy with compression and treated with PBS. MP group was performed with laminectomy with compression and treated with MP (100 mg/kg per day for 3 days). Rutin group was performed with laminectomy with compression and treated with Rutin (30 mg/kg per day for 3 days). Con: Control; SCI: spinal cord injury; MP: methylprednisolone.](NRR-13-128-g008){#F7}

Discussion {#sec1-4}
==========

With the rise in modern transportation, mining and industry, SCI has become increasingly common in China. SCI is a debilitating injury that negatively impacts human health and the quality of life. In this study, we demonstrate, for the first time, that rutin is neuroprotective in SCI. Rutin increased the BBB scores and reduced spinal cord water content in rats with SCI.

Oxidative stress after SCI plays a major pathogenetic role in secondary injury, and free radical levels are an indicator of the degree of injury (Song et al., 2015; Wang et al., 2015; Colón and Miranda, 2016). Strategies that prevent or reduce oxidative stress have shown therapeutic efficacy for SCI (Tian et al., 2016). Indeed, in the present study, rutin reduced MDA content and increased the concentrations of SOD and catalase and increased the activity of GSH-Px in the rat models of SCI, suggesting that the flavonoid protects cells of the spinal cord by reducing oxidative stress (Bhandary et al., 2012; Warford et al., 2014). The rutin reduced MDA concentrations and elevated SOD levels (Su et al., 2014). Scholars demonstrated that rutin improved spatial memory by attenuating oxidative stress and neuroinflammation in Alzheimer\'s disease transgenic mice (Xu et al., 2014; Wu et al., 2016).

Inflammatory cytokines regulate the immune response and participate in cross-talk between immune cells and other cell types (Miller et al., 2013; Xie et al., 2014). NF-κB is a transcription complex that plays a key role in cytokine-mediated inflammatory reactions (Chen et al., 2014b; Kang et al., 2015; Zhang et al., 2015). NF-κB induces transcription of numerous inflammatory cytokines during the early stage, including TNF-α, IL-1β and IL-6, thereby increasing the inflammatory response (Shin et al., 2011; Du et al., 2013).

In this study, the levels of NF-κB p65, TNF-α, IL-1β and IL-6 were reduced by rutin treatment in the rat SCI model (Paniagua-Torija et al., 2015). This anti-inflammatory effect of rutin might contribute to the neuroprotection provided by the flavonoid. Our findings are consistent with previous studies. Previous studies showed that rutin decreased TNF-α and IL-1β generation in microglia (Wang et al., 2012; Zong et al., 2012). Furthermore, Abd-El-Fattah et al. (2010) reported that rutin exerted an anti-inflammatory effect in irradiated rats with cerebral ischemia/reperfusion injury.

Inactive p38 MAPK is mainly distributed in the cytoplasm, and translocates to the nucleus upon activation to regulate gene expression through phosphorylation of transcription factors (Tang et al., 2013; Chen et al., 2014a). Extracellular stimuli, such as inflammatory cytokines, induce the phosphorylation and activation of p38 MAPK *via* a kinase cascade (Zhu et al., 2013; Park et al., 2015). Activated p38 MAPK induces the expression of enzymes, such as COX and iNOS, as well as numerous inflammatory-related molecules, which mediate the inflammatory response (Breton-Romero and Lamas, 2013).

In this study, we observed that p38 MAPK expression in the SCI model was reduced by rutin, suggesting that it may, in part, protect cells in the spinal cord by lowering the expression of pro-apoptotic proteins. Our results are in line with those of other studies. For example, Park et al. (2014) observed that rutin protected human dopaminergic cells against rotenone-induced injury by inhibiting the p38 MAPK signaling pathway. A previous study showed that rutin exerted anti-inflammatory effects, which were attributable to its suppression of p38 MAPK in UVB-irradiated mouse skin (Choi et al., 2014). Importantly, we found that reduction of caspase-9 and caspase-3 activities are the key to the neuroprotective action of rutin on spinal cord cells. This observation was in accordance with previous reports showing that rutin alleviated prion peptide-induced cell death by inhibiting caspase-3 activity in dopaminergic and hippocampal neurons (Na et al., 2014; Song et al., 2014).

In summary, our findings demonstrate that rutin protects spinal cord cells by reducing oxidative stress and inflammation, and by lowering the expression of pro-apoptotic proteins *via* inhibition of the p38 MAPK pathway. Rutin plays an important role in the treatment of various disorders, and has been applied in health-care system due to its wide pharmacological activities, lower cost and high safety margins which is the most significant preponderance compare with the glucocorticoids (Sharma et al., 2013). In contrast, glucocorticoids have a wide foreseeable range of side effects; for instance, patients receiving high-dose MP after SCI had a significantly increased risk of major complications, in particular, gastrointestinal ulcer/bleeding and pulmonary embolism (Chikuda et al., 2014; Evaniew et al., 2015). However, the major problem associated with rutin is its poor solubility in aqueous media (0.8 mg/mL) (Lauro et al., 2002), which means poor bioavailability.

In the near future, enhancing its bioavailability using novel drug delivery methods and fully elucidating the neuroprotective effects and mechanisms of action will add evidence for use of traditional Chinese medicine for treatment of SCI.
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